Later, in a successful clinical trial, FDA approved the combination of trastuzumab and docetaxel to treat metastatic breast cancer (26), which can improve the survival endpoint and quality of life of patients with advanced HER2 positive breast cancer who receive chemotherapy. Here, ERBB2 is linked to breast carcinoma.